Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem

Jane Koo, Jeffrey J. Auletta, David M. Hartley, John Huber, Samantha Jaglowski, Malika Kapadia, Katilyn Kusnier, Leslie Lehmann, Joseph Maakaron, Kasiani C. Myers, Ahna Pai, Loretta Parker, Rachel Phelan, Christine Sper, Seth J. Rotz, Christopher E. Dandoy

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly impacted global health and healthcare delivery systems. To characterize the secondary effects of the COVID-19 pandemic and mitigation strategies used in the delivery of hematopoietic stem cell transplantation (HSCT) care, we performed a comprehensive literature search encompassing changes in specific donor collection, processing practices, patient outcomes, and patient-related concerns specific to HSCT and HSCT-related healthcare delivery. In this review, we summarize the available literature on the secondary impacts the COVID-19 pandemic on the fields of HSCT and cellular therapy. The COVID-19 pandemic has had numerous secondary impacts on patients undergoing HSCT and the healthcare delivery systems involved in providing complex care to HSCT recipients. Institutions must identify these influences on outcomes and adjust accordingly to maintain and improve outcomes for the transplantation and cellular therapy community.

Original languageEnglish (US)
Pages (from-to)737-746
Number of pages10
JournalTransplantation and Cellular Therapy
Volume28
Issue number11
DOIs
StatePublished - Nov 2022

Bibliographical note

Funding Information:
Financial disclosure: S.R. received support from the National Center for Advancing Translational Sciences (2KL2TR002547; Raed Dweik, principal investigator). Conflict of interest statement: R.P. reports serving on an advisory board for bluebird bio and receipt of research funding from Amgen. C.D. reports honoraria from Omeros and Alexion Pharmaceuticals. The other authors have no conflicts of interest to report. Financial disclosure: See Acknowledgments on page XXX.

Funding Information:
Financial disclosure: S.R. received support from the National Center for Advancing Translational Sciences (2KL2TR002547; Raed Dweik, principal investigator).

Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy

Keywords

  • COVID-19
  • Cell therapy
  • Coronavirus
  • Cryopreservation
  • Healthcare delivery
  • Hematopoietic stem cell transplantation
  • Mitigation strategies
  • SARS-CoV-2
  • Severe acute respiratory syndrome

Fingerprint

Dive into the research topics of 'Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem'. Together they form a unique fingerprint.

Cite this